Repurposing, repositioning - by whatever name, the 505(b)(2) drug development pathway is gaining traction. I will be giving a talk entitled “505(b)(2) Product Candidate Selection-Which Old Dog to Rejuvenate” on December 10 at the Drug Repurposing Strategies meeting. The conference costs $1695 but friends of Camargo can get a $400 discount - just contact me [...]
Search
About
You are currently browsing the Drug Kennel weblog archives for the day Friday, November 7th, 2008.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- Failed 505(b)(2)?: Vivus’ Qnexa
- Will We Have Generic User Fees? Public Meeting To Be Held.
- Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?
- Generic Lovenox – 505j or 505(b)(2)
- New User Fees for 2011
- Still submitting paper ANDA applications?
- What should a license cost?
- Avandia: Who Won?
- Advisory Committee Meeting: Rosiglitazone
- The skinny on a potential new treatment of obesity